For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
MOTS-c is the only peptide in this research series encoded by mitochondrial (not nuclear) DNA. A mitochondrial-derived 16-amino acid peptide discovered in 2015, it functions as an exercise-induced signaling molecule that activates AMPK via the folate-methionine cycle. Its CB4211 analog completed a Phase 1b NAFLD trial showing significant liver enzyme and glucose improvement. No human therapeutic trials for MOTS-c itself exist.
MOTS-c has not been clinically tested in humans as a therapeutic peptide, and preclinical models have not thoroughly evaluated its safety. The closest human data comes from CB4211, a synthetic, stabilized analog of MOTS-c, which completed a Phase 1a/1b trial in 65 healthy adults (Phase 1a) and 20 obese NAFLD patients (Phase 1b). Clinical development for CB4211 has since been discontinued by CohBar Inc. due to persistent injection site reactions related to formulation. MOTS-c itself remains unapproved worldwide.
The CB4211 discontinuation was a technical formulation failure, not a biological failure of the MOTS-c approach. The Phase 1b trial met its primary safety endpoint and showed significant improvements in liver enzymes and glucose. The door remains open for better-formulated analogs or alternative delivery routes.
MOTS-c is not listed on the WADA Prohibited List as of 2026, but the US Anti-Doping Agency has specifically identified it as a substance of interest given its exercise-mimicking properties. Athletes subject to anti-doping testing should verify current status annually.
MOTS-c (Mitochondrial ORF of the 12S rRNA Type-C) is the only compound in this research series encoded not by nuclear DNA but by the mitochondrial genome, a discovery that fundamentally expanded scientific understanding of what the mitochondrial genome can do. It is a mitochondrial-derived peptide composed of 16 amino acids encoded by the 12S rRNA region of the mitochondrial genome.
Under metabolic stress, MOTS-c in cells can be transferred to the nucleus in an AMPK-dependent manner and bind to transcription factors regulated by antioxidant response elements (ARE), thereby improving the stress resistance of cells. MOTS-c plays the role of endocrine-like factors by regulating nuclear transcription to restore homeostasis.
MOTS-c was first described in 2015 by Lee et al. in Cell Metabolism, making it the youngest compound in this research series by a wide margin. Despite its young age, it has already generated Nature Communications publications, Phase 1 human trial data through its analog CB4211, and identification of a genetic polymorphism associated with human longevity.
MOTS-c gene polymorphisms have been found to be associated with human lifespan. Circulating levels of MOTS-c decline with age: blood MOTS-c levels in young people are 11% and 21% higher than those in middle- and old-aged people, respectively. This age-dependent decline makes MOTS-c particularly compelling as a longevity target.
MOTS-c plays its physiological functions mainly through activating the AICAR-AMPK signaling pathways by disrupting the folate-methionine cycle in cells. This folate cycle disruption leads to AICAR accumulation, which activates AMPK, the cell's master energy sensor. AMPK is the same pathway activated by metformin and exercise, positioning MOTS-c as a mitochondrially-encoded signal that coordinates the entire cell's response to energy stress, operating upstream of many of the most important metabolic regulatory nodes.
Under metabolic stress, MOTS-c translocates from mitochondria to the nucleus in an AMPK-dependent manner and binds to transcription factors regulated by antioxidant response elements (ARE). This nuclear translocation and transcription factor binding is what distinguishes MOTS-c from other AMPK activators: it directly regulates gene expression programs through ARE-mediated transcriptional control, not just by activating a kinase cascade.
A 2024 study revealed that MOTS-c directly binds to a protein kinase called CK2alpha, but with opposite effects in different tissues: in skeletal muscle, it activates CK2alpha to promote muscle function and repair, while in adipose tissue, it inhibits its activity to reduce fat storage. This tissue-specific tailored action makes MOTS-c a key player in maintaining whole-body metabolic health in a targeted way.
Recent studies have shown that MOTS-c hormonal effects are achieved through regulation of genes such as GLUT4, STAT3, and IL-10. It influences energy metabolism, insulin resistance, inflammatory response, exercise adaptation, aging, and aging-related pathologies. MOTS-c interactions with NRF2 can improve the expression of mitochondrial protective genes.
In high-fat diet fed male mice, MOTS-c (0.5 mg/kg/day intraperitoneally for 3 weeks) prevented weight gain, improved glucose homeostasis, and reduced the accumulation of lipids in the liver. MOTS-c did not impact food intake, but instead increased energy expenditure, as indicated by increased heat output. These mice had less fat accumulation due to increased carbohydrate usage, increased beta oxidation of fatty acids, and thus less fat storage. The metabolic effects stem from the activation of AMPK, a central mediator of energy homeostasis.
Plasma MOTS-c levels are lower in obese male children and adolescents, and are negatively correlated with markers of insulin resistance. MOTS-c levels are also positively correlated with coronary endothelial function in humans. MOTS-c improves endothelial function in rats.
MOTS-c treatment effectively delayed weight gain in diabetic rats, consistent with research in HFD-induced obese mice. MOTS-c treatment has been demonstrated to lower blood glucose levels in T1D mice, T1D rats, and gestational diabetic mice.
Important: the metabolic beneficial effects were observed in male mice and postmenopausal female mice but not in pre-menopausal female mice, revealing a sexual dimorphism of MOTS-c biology that has significant implications for trial design.
The metabolic data is MOTS-c's most consistently replicated and mechanistically grounded body of work, reproducible across multiple independent laboratories in multiple rodent models of both type 1 and type 2 diabetes and obesity. The human correlational data (lower MOTS-c in obese children, T2D patients) provides epidemiological plausibility. The sexual dimorphism finding, where benefits appear stronger in males and postmenopausal females but not pre-menopausal females, is an important and underexplored nuance that has significant implications for trial design and patient selection.
MOTS-c can significantly enhance physical performance in young (2 month), middle-age (12 month), and old (22 month) mice. Evidence shows that late-life (23.5 month) initiated intermittent MOTS-c treatment (3 times per week) can increase physical capacity and healthspan in mice. In humans, exercise induces endogenous MOTS-c expression in skeletal muscle and in circulation.
In muscle cells, levels of MOTS-c significantly increased nearly 12-fold after exercise and remained partially elevated after a four-hour rest, while MOTS-c levels in blood plasma also increased by approximately 50% during and after exercise and then returned to baseline after the rest period. The findings suggest that exercise itself induces the expression of this mitochondrial-encoded regulatory peptide.
A 2024 study revealed that MOTS-c directly binds to a protein kinase called CK2alpha, but with opposite effects in different tissues: in skeletal muscle, it activates CK2alpha to promote muscle function and repair, while in adipose tissue, it inhibits its activity to reduce fat storage. This ability to provide tissue-specific tailored instruction makes it a key player in maintaining whole-body metabolic health.
The Nature Communications 2021 publication is one of the landmark papers in MOTS-c research: a high-impact, multi-age-group study from the USC Leonard Davis School of Gerontology that demonstrated physical performance restoration in old mice to near-young levels and, crucially, showed that exercise itself triggers an approximately 12-fold rise in endogenous MOTS-c in human skeletal muscle. This is direct human correlational evidence for MOTS-c as an exercise-induced signaling molecule, even without a therapeutic trial. The 2024 CK2alpha binding paper adds mechanistic precision that further strengthens the skeletal muscle case.
The Phase 1a stage of the study was a double-blind, placebo-controlled single ascending dose and multiple ascending dose assessment of safety, tolerability, and pharmacokinetics over one week in 65 healthy adults. The Phase 1b study was a randomized, double-blind, placebo-controlled evaluation of a 25 mg dose of CB4211 given once daily by subcutaneous injection for four weeks in 20 obese subjects with nonalcoholic fatty liver disease.
The study met its primary endpoint showing that CB4211 was well-tolerated and appeared safe with no serious adverse events. Relative to placebo, levels of liver enzymes ALT and AST were reduced with CB4211 treatment by 25% and 17%, respectively. Significant reductions in blood glucose were demonstrated. Liver fat reduction based on MRI-PDFF measures was comparable between the groups (-5.03% vs -4.88%), which was not unexpected in a 28-day study.
Clinical development for CB4211 was discontinued due to persistent injection site reactions attributed to formulation issues, specifically evidence that some of the CB4211 remained at the injection site. This was a technical formulation failure, not a biological failure of the MOTS-c approach.
This is the most important human data point in the MOTS-c story. The CB4211 Phase 1b trial achieved statistically significant liver enzyme improvement and glucose reduction in only 28 days, an impressive signal given the trial's small size and short duration. The 25% ALT and 17% AST reductions compare favorably with Phase 3 candidates for NASH at similar timepoints. The discontinuation due to injection site reactions, not safety or efficacy concerns, is a technical formulation failure, not a biological failure of the MOTS-c approach. The biological proof-of-concept established by CB4211 remains valid.
MOTS-c levels decrease with aging and senescence in pancreatic islet cells. Treating aged C57BL/6 mouse pancreatic islets with MOTS-c reduced pancreatic islet senescence by modulating nuclear gene expression and metabolites involved in beta-cell senescence. MOTS-c treatment improved pancreatic islet senescence and glucose intolerance in S961-treated C57BL/6 and in nonobese diabetic mice.
MOTS-c prevents autoimmune beta-cell destruction by targeting T cells in non-obese diabetic mice. Treatment with MOTS-c for non-obese diabetic mice shows that MOTS-c re-programs T cell metabolism toward a less inflammatory phenotype, preventing the autoimmune destruction of islet cells rather than simply compensating for it downstream.
The T1D data is particularly striking because MOTS-c does not merely improve metabolic signaling downstream of pancreatic failure: it appears to directly protect the islet cells themselves from autoimmune T cell attack by modulating T cell metabolism. This immune modulatory dimension, acting on T cells rather than only on metabolic tissue, substantially expands MOTS-c's theoretical application space and connects it to the broader autoimmune and immune-oncology field. The 2025 publication represents the most recent confirmation of this mechanism. All data is preclinical.
MOTS-c treatment observed an 8% decrease in left ventricular wall thickness in the treated diabetic group, highlighting the potential beneficial effects of MOTS-c on restoring cardiac dysfunction as consistently reported in previous studies on T1D models.
The 2024 Asil et al. study in European Journal of Pharmacology is notable for measuring endogenous MOTS-c levels in actual human heart failure patients treated with SGLT-2 inhibitors, a real-world human biomarker study that documents the association between MOTS-c and cardiac outcomes. MOTS-c levels positively correlate with coronary endothelial function in humans. The 2025 Frontiers in Physiology paper confirmed that MOTS-c restores mitochondrial respiration in the type 2 diabetic heart, providing the most recent mechanistic confirmation.
The cardiovascular evidence spans human biomarker associations and rodent cardiac protection models. The cardiac data is mechanistically well-grounded: MOTS-c's AMPK activation promotes mitochondrial biogenesis and energy efficiency in cardiomyocytes, directly relevant to the energetic deficits driving heart failure. The 2024 human biomarker study is the most clinically relevant data point, documenting MOTS-c's association with cardiac outcomes in real heart failure patients even without a therapeutic trial. No human cardiac therapeutic trials exist.
By activating the AMPK pathway and preventing bone marrow-derived macrophages from differentiating into osteoclasts, MOTS-c prevents bone loss caused by estrogen deficiency. MOTS-c inhibited RANKL and upregulates the rate of OPG/RANKL in osteocytes, leading to inhibition of osteoclastogenesis.
By suppressing inflammation via restraining NF-κB depending on the AMPK-PGC1alpha-ROS axis pathway and STAT1 pathway, MOTS-c prevents osteoclast development in animal models of osteolysis. MOTS-c injection into the area where ultra-high molecular weight polyethylene particles were implanted prevented significant bone mass loss and substantially reversed bone loss.
The osteoporosis data is multi-mechanistic and spans both estrogen-deficiency models (directly relevant to postmenopausal women) and implant-associated osteolysis models (relevant to orthopedic medicine). Three separate biological mechanisms are documented: RANKL/OPG pathway modulation, TGF-beta/Smad-mediated osteoblast stimulation, and NF-κB anti-inflammatory osteoclast suppression. This triple mechanism convergence on bone density preservation is preclinically robust but entirely unvalidated in humans.
MOTS-c treatment reduced both the weight gain and the insulin resistance associated with experimental menopause. Furthermore, MOTS-c suppressed the increase in inflammatory markers such as IL-1beta and IL-6 in adipose tissue.
In a post-menopause model of ovariectomized mice, the administration of MOTS-c led to increased brown fat activation and inflammatory markers in white adipose tissue, lower fatty acid levels in serum and liver, along with limited weight gain. MOTS-c activated AMPK to minimize fat deposition, restore energy, and improve insulin sensitivity.
The postmenopausal data is particularly clinically valuable given the enormous unmet need in this population for non-hormonal treatments that address the concurrent problems of metabolic dysfunction, weight gain, and bone loss. MOTS-c addresses all three simultaneously in the ovariectomy model. The sex-specific biology of MOTS-c, its effects appear strongest in males and estrogen-depleted females but not in pre-menopausal females, may actually define its ideal clinical population rather than being a limitation.
Aging is a major risk factor associated with Alzheimer's disease. MOTS-c has been shown to have beneficial effects in age-related diseases including Alzheimer's disease. Peripheral administration of a cell-penetrating MOTS-c analogue attenuated Aβ1-42 or LPS-induced memory impairment through inhibiting neuroinflammation.
MOTS-c mainly acts through the Folate-AICAR-AMPK pathway, influencing energy metabolism, insulin resistance, inflammatory response, exercise, aging, and aging-related pathologies. MOTS-c interactions with NRF2 can improve the expression of mitochondrial protective genes.
The neurodegeneration data is the youngest and least developed application area for MOTS-c. The Jiang et al. 2021 study using a cell-penetrating MOTS-c analog (necessary because the native peptide may not cross the blood-brain barrier efficiently) is an important methodological advance. No human neurological trial data exists. The mechanistic case, AMPK activation reduces neuroinflammation and improves neuronal energy metabolism, both key drivers of AD pathology, is sound, but the translational distance remains large.
The mitochondrial-derived peptide MOTS-c inhibits ovarian cancer by targeting LARS1 (leucyl-tRNA synthetase 1), representing a newly identified anti-tumor mechanism for this mitochondrial-encoded peptide. The finding is mechanistically novel and consistent with MOTS-c's broader ability to modulate gene expression programs in pathological states.
This is the most early-stage and exploratory application in the MOTS-c literature. A single 2023 preclinical publication identified LARS1 as a target through which MOTS-c exerts anti-ovarian cancer effects. The finding is mechanistically novel but the evidence base is a single preclinical study requiring independent replication before drawing any conclusions.
Limited human data. 10-20mg from animal studies scaled to humans.
MOTS-c as a therapeutic peptide has no validated human dosing protocol. All dosing information reflects either the CB4211 analog trial (which used a modified, stabilized version) or rodent preclinical studies. The CB4211 25 mg once-daily SubQ protocol is the only reference point with any human pharmacokinetic data. Research-grade quality standards: HPLC purity 98% or above, mass spec confirmation of the 16-AA sequence, endotoxin below 1 EU/mg for injectable use. The sexual dimorphism of MOTS-c effects (benefits stronger in males and postmenopausal females) is an underappreciated dosing and patient selection consideration.
MOTS-c vs. SS-31 (Mitochondrial Comparison): Both target mitochondrial biology but through fundamentally different mechanisms. SS-31 is an exogenous peptide that stabilizes mitochondrial membrane architecture from the outside by binding cardiolipin. MOTS-c is a signal from within the mitochondrial genome itself that translocates to the nucleus to regulate gene expression. SS-31 has FDA accelerated approval (Barth syndrome) and multiple Western Phase 2 trials. MOTS-c has no approved therapeutic use but has human correlational data confirming its role as an exercise-induced signal, which SS-31 does not.
MOTS-c vs. Thymosin Alpha-1 (Metabolic-Immune Overlap): Both have been studied in the context of diabetes and immune modulation, but through entirely different mechanisms. Tα1 modulates T-cell function through TLR signaling; MOTS-c re-programs T cell metabolism through AMPK-mediated mitochondrial biogenesis. Tα1 has 30+ years of clinical data and approvals in 35+ countries; MOTS-c has one discontinued analog trial. Their potential combination in autoimmune diabetes (T1D) would target complementary immune pathways.
MOTS-c has not been clinically tested in humans as a therapeutic peptide, and preclinical models have not thoroughly evaluated its safety. This is the most significant safety limitation: the absence of systematic safety characterization.
The CB4211 Phase 1a/1b study (CB4211 being a MOTS-c analog) met its primary endpoint showing that CB4211 was well-tolerated and appeared safe with no serious adverse events. The most common adverse event was persistent injection site reactions attributed to formulation issues rather than the molecule's inherent toxicity. This led to program discontinuation.
Self-experimenter reports include increased heart rate or heart palpitations and injection site reactions, per the US Anti-Doping Agency. These reports should not be taken as a formal safety characterization but do highlight that unsupervised use carries real unknowns.
Given that MOTS-c's primary mechanism is AMPK activation (an effect that overlaps with the well-studied drug metformin), the theoretical safety profile is relatively favorable. However, AMPK is a master regulator, and sustained nonphysiological AMPK activation could theoretically have off-target effects in tissues not intended to be targeted. This has not been systematically studied. The sexual dimorphism finding (effects differ between males and premenopausal females) raises additional questions about sex-specific safety considerations.
MOTS-c is the most scientifically novel compound reviewed in this research series. Every other peptide has a multi-decade research history. MOTS-c was first described in 2015, yet has already generated Nature Communications publications, Phase 1 human trial data through its analog, and identification of a polymorphism associated with human longevity.
Its uniqueness as a mitochondrially-encoded peptide that translocates to the nucleus to regulate gene expression, functioning simultaneously as a myokine, exercise mimetic, metabolic hormone, and stress-response coordinator, distinguishes it mechanistically from every other compound in this series. It shares territory with SS-31 (mitochondrial targeting defines both) but where SS-31 stabilizes mitochondrial structure from the outside, MOTS-c is a signal from within the mitochondrial genome itself.
The CB4211 discontinuation was a formulation failure, not a biological failure. The Phase 1b human data was genuinely encouraging: 25% ALT reduction, 17% AST reduction, and significant glucose improvement in 28 days in NASH patients. What MOTS-c needs most is a well-funded, technically sophisticated development program willing to solve the delivery challenge. Given the scale of the metabolic disease epidemic globally (diabetes, NASH, obesity, sarcopenia), the clinical imperative for a mitochondrially-encoded exercise mimetic could hardly be higher.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use